Details for Patent: 9,840,492

Which drugs does patent 9,840,492 protect, and when does it expire?

Patent 9,840,492 protects VIVJOA and is included in one NDA.

This patent has twenty patent family members in eighteen countries.

Summary for Patent: 9,840,492

Title:	Antifungal compounds and processes for making
Abstract:	The present invention relates to polymorphic forms of compound 1 or 1a and processes for preparing compound 1 and 1a polymorphs, which are useful as antifungal agents. In particular, the invention seeks to provide a new methodology for preparing polymorphs of compound 1 and substituted derivatives thereof.
Inventor(s):	Hoekstra; William J. (Durham, NC), Wirth; David Dale (Oak Ridge, NC), Ehiwe; Tracy (Cambridge, GB), Bonnaud; Thierry (Cambridge, GB)
Assignee:	Viamet Pharmaceuticals, Inc. (Durham, NC)
Application Number:	15/317,006
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 9,840,492

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 9,840,492

PCT Information
PCT Filed	March 17, 2016	PCT Application Number:	PCT/US2016/022858
PCT Publication Date:	September 22, 2016	PCT Publication Number:	WO2016/149486

International Family Members for US Patent 9,840,492

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016233113
Brazil	112017018823
Canada	2978339